MARKET

CLLS

CLLS

Cellectis
NASDAQ
2.670
+0.100
+3.89%
After Hours: 2.670 0 0.00% 16:00 03/27 EDT
OPEN
2.560
PREV CLOSE
2.570
HIGH
2.710
LOW
2.502
VOLUME
7.36K
TURNOVER
0
52 WEEK HIGH
3.774
52 WEEK LOW
0.9628
MARKET CAP
148.41M
P/E (TTM)
-2.2073
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CLLS last week (0318-0322)?
Weekly Report · 3d ago
Cibus Inc <CBUS.OQ> expected to post a loss of $1.43 a share - Earnings Preview
Cibus Inc expected to post a loss of $1.43 a share - Earnings Preview. The company is expected to show a rise in quarterly revenue when it reports results on March 21 for the period ending December 31 2023. Cibus expected to report a 815.5% increase in revenue.
Reuters · 03/19 21:23
Weekly Report: what happened at CLLS last week (0311-0315)?
Weekly Report · 03/18 09:41
Earnings week ahead: FedEx, Nike, XPeng, Tencent, General Mills and more
Earnings week of March 18 to 22 will feature major quarterly updates from FedEx, XPeng, Tencent, General Mills and more. The week will also feature important announcements from Nike, Lululemon Athletica and Chewy. Technology companies are also in focus with earnings results from Micron, Accenture and others.
Seeking Alpha · 03/17 12:20
Weekly Report: what happened at CLLS last week (0304-0308)?
Weekly Report · 03/11 09:40
Monthly information on share capital and company voting rights
Barchart · 03/04 15:30
Weekly Report: what happened at CLLS last week (0226-0301)?
Weekly Report · 03/04 09:41
Cibus Inc <CBUS.OQ> expected to post a loss of $1.43 a share - Earnings Preview
Cibus Inc expected to post a loss of $1.43 a share - Earnings Preview. The company is expected to show a rise in quarterly revenue when it reports results on March 1 for the period ending December 31 2023.
Reuters · 02/28 21:03
More
About CLLS
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Webull offers Cellectis SA (ADR) stock information, including NASDAQ: CLLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLLS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLLS stock methods without spending real money on the virtual paper trading platform.